TER-EYENCT06905834
Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments
At risk: Primary completion moved at least 1 year 6 months later.
See at-risk trials from Instituto de Investigación Biomédica de Salamanca
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jun 2027 to Jan 2029 Show 4 more changesShow less
- Start date pushed from Oct 2026 to Dec 2026
- Eligibility criteria expanded, about 16 words
- Study completion pushed from Jun 2028 to Jun 2030
- Secondary endpoints: details revised at 3 of 4 entries
- Notable Start date: May 2026 to Oct 2026v4
- Notable Start date: Jun 2025 to May 2026v3
- Notable Eligibility criteria expanded, about 7 words
- Secondary endpoints: details revised at 3 of 4 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (4)
Arms and interventions
6.25 million mesenchymal cells will be injected subconjunctivally into each subject in the group. These cells will be in a 2.5 mL suspension of Lactated Ringer's solution, to which 1% HSA will have been added beforehand.
12.5 million mesenchymal cells will be injected subconjunctivally into each subject in the group. These cells will be in a 2.5 mL suspension of Lactated Ringer's solution, to which 1% HSA will have been added beforehand.
Drugs: Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC